About The Chemours (NYSE:CC)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging. The Fluoroproducts segment provides fluoroproducts, including refrigerants, and industrial fluoropolymer resins and derivatives under the Teflon, Viton, Krytox, and Nafion brand names. The Chemical Solutions segment offers industrial and specialty chemicals for gold production, oil and gas, water treatment, electronics, and automotive industries. It also provides sodium cyanide through its mining solutions business; and performance chemicals and intermediates, such as methylamines, glycolic acid, and Vazo free radical initiators. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Industry Chemicals & allied products
Sub-IndustryN/A
SectorBasic Materials
SymbolNYSE:CC
CUSIPN/A
Phone302-773-1000
Debt
Debt-to-Equity Ratio4.74%
Current Ratio2.12%
Quick Ratio1.55%
Price-To-Earnings
Trailing P/E Ratio13.59
Forward P/E Ratio9.67
P/E Growth0.63
Sales & Book Value
Annual Sales$6.18 billion
Price / Sales1.53
Cash Flow$5.4423 per share
Price / Cash9.54
Book Value$4.67 per share
Price / Book11.12
Profitability
EPS (Most Recent Fiscal Year)$3.82
Net Income$746 million
Net Margins12.06%
Return on Equity115.54%
Return on Assets10.83%
Miscellaneous
Employees7,000
Outstanding Shares182,520,000
The Chemours (NYSE:CC) Frequently Asked Questions
What is The Chemours' stock symbol?
The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."
How often does The Chemours pay dividends? What is the dividend yield for The Chemours?
The Chemours declared a quarterly dividend on Friday, December 1st. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.17 per share on Thursday, March 15th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from The Chemours's previous quarterly dividend of $0.03. View The Chemours' Dividend History.
How will The Chemours' stock buyback program work?
The Chemours announced that its board has authorized a share repurchase program on Monday, December 4th 2017, which authorizes the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board believes its stock is undervalued.
How were The Chemours' earnings last quarter?
The Chemours Company (NYSE:CC) issued its quarterly earnings data on Wednesday, February, 14th. The specialty chemicals company reported $1.19 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.95 by $0.24. The specialty chemicals company earned $1.58 billion during the quarter, compared to analyst estimates of $1.55 billion. The Chemours had a return on equity of 115.54% and a net margin of 12.06%. The firm's revenue for the quarter was up 19.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.08 EPS. View The Chemours' Earnings History.
When is The Chemours' next earnings date?
What guidance has The Chemours issued on next quarter's earnings?
The Chemours issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of $4.95-5.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.09.
What price target have analysts set for CC?
10 equities research analysts have issued twelve-month price objectives for The Chemours' shares. Their predictions range from $55.00 to $68.00. On average, they anticipate The Chemours' share price to reach $59.65 in the next twelve months. View Analyst Ratings for The Chemours.
Who are some of The Chemours' key competitors?
Some companies that are related to The Chemours include Asahi Kasei (AHKSY), FMC (FMC), Johnson Matthey (JMPLY), Huntsman (HUN), Olin (OLN), W. R. Grace and (GRA), Ashland (ASH), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), GCP Applied Technologies (GCP), PQ Group (PQG), Innospec (IOSP), KMG Chemicals (KMG), Nexeo Solutions (NXEO), Innophos (IPHS), OCI Partners (OCIP) and Hawkins (HWKN).
Who are The Chemours' key executives?
The Chemours' management team includes the folowing people:
- Mr. Mark P. Vergnano, Pres, CEO & Director (Age 60)
- Mr. Mark E. Newman, Sr. VP & CFO (Age 55)
- Mr. David C. Shelton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Mr. E. Bryan Snell, Pres of Titanium Technologies (Age 61)
- Mr. Paul Kirsch, Pres of Fluoroproducts Bus. (Age 54)
Has The Chemours been receiving favorable news coverage?
News headlines about CC stock have been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. The Chemours earned a coverage optimism score of 0.36 on Accern's scale. They also gave news articles about the specialty chemicals company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of The Chemours?
Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Chemours' stock price today?
One share of CC stock can currently be purchased for approximately $51.92.
How big of a company is The Chemours?
The Chemours has a market capitalization of $9.54 billion and generates $6.18 billion in revenue each year. The specialty chemicals company earns $746 million in net income (profit) each year or $3.82 on an earnings per share basis. The Chemours employs 7,000 workers across the globe.
How can I contact The Chemours?
The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19899. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]
MarketBeat Community Rating for The Chemours (CC)
MarketBeat's community ratings are surveys of what our community members think about The Chemours and other stocks. Vote "Outperform" if you believe CC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CC will underperform the S&P 500 over the long term. You may vote once every thirty days.
The Chemours (NYSE:CC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for The Chemours in the last 12 months. Their average twelve-month price target is $59.65, suggesting that the stock has a possible upside of 14.89%. The high price target for CC is $68.00 and the low price target for CC is $55.00. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.70 | 2.67 | 2.75 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $59.65 | $57.9444 | $58.00 | $51.5714 |
| Price Target Upside: | 14.89% upside | 8.13% upside | 25.36% upside | 16.13% upside |
The Chemours (NYSE:CC) Consensus Price Target History
The Chemours (NYSE:CC) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
The Chemours (NYSE:CC) Dividend Information
The Chemours pays an annual dividend of $0.68 per share, with a dividend yield of 1.31%. CC's most recent quarterly dividend payment was Thursday, March 15. The Chemours pays out 17.80% of its earnings out as a dividend.
| Most Recent Dividend: | 3/15/2018 |
| Annual Dividend: | $0.68 |
| Dividend Yield: | 1.31% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 17.80% (Trailing 12 Months of Earnings)
12.66% (Based on This Year's Estimates)
11.39% (Based on Next Year's Estimates)
|
| Frequency: | Quarterly Dividend |
The Chemours (NYSE:CC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/1/2017 | Quarterly | $0.17 | 1.43% | 2/14/2018 | 2/15/2018 | 3/15/2018 |
| 11/7/2017 | quarterly | $0.03 | 0.24% | 11/17/2017 | 11/20/2017 | 12/15/2017 |
| 8/2/2017 | quarterly | $0.03 | 0.25% | 8/15/2017 | 8/17/2017 | 9/15/2017 |
| 4/27/2017 | quarterly | $0.03 | 0.3% | 5/15/2017 | 5/17/2017 | 6/15/2017 |
| 2/14/2017 | quarterly | $0.03 | 0.37% | 2/23/2017 | 2/27/2017 | 3/15/2017 |
| 11/2/2016 | quarterly | $0.03 | 0.72% | 11/15/2016 | 11/17/2016 | 12/15/2016 |
| 8/3/2016 | quarterly | $0.03 | 1.34% | 8/15/2016 | 8/17/2016 | 9/15/2016 |
| 4/27/2016 | quarterly | $0.03 | 1.27% | 5/13/2016 | 5/17/2016 | 6/15/2016 |
| 2/23/2016 | quarterly | $0.03 | 2.44% | 3/9/2016 | 3/11/2016 | 3/31/2016 |
| 9/1/2015 | quarterly | $0.03 | 1.38% | 11/10/2015 | 11/13/2015 | 12/14/2015 |
| 7/24/2015 | special | $0.55 | | 7/30/2015 | 8/3/2015 | 9/11/2015 |
(Data available from 1/1/2013 forward)
The Chemours (NYSE CC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.75%
Institutional Ownership Percentage: 77.80%
The Chemours (NYSE CC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Erich Parker | SVP | Sell | 5,000 | $52.00 | $260,000.00 | |  |
| 3/9/2018 | Mark Newman | VP | Sell | 29,381 | $49.19 | $1,445,251.39 | | |
| 2/20/2018 | Paul Kirsch | Insider | Sell | 13,770 | $50.01 | $688,637.70 | 63,093 | |
| 12/13/2017 | Christian W. Siemer | Insider | Sell | 15,088 | $47.37 | $714,718.56 | | |
| 11/6/2017 | E Bryan Snell | Insider | Sell | 11,878 | $53.25 | $632,503.50 | 63,063 | |
| 10/13/2017 | David C Shelton | SVP | Sell | 5,908 | $56.01 | $330,907.08 | 47,356 | |
| 10/10/2017 | David C Shelton | SVP | Sell | 13,397 | $55.00 | $736,835.00 | | |
| 10/5/2017 | David C Shelton | SVP | Sell | 19,000 | $53.68 | $1,019,920.00 | | |
| 9/5/2017 | E Bryan Snell | Insider | Sell | 13,000 | $49.35 | $641,550.00 | | |
| 8/31/2017 | David C. Shelton | SVP | Sell | 13,337 | $48.48 | $646,577.76 | | |
| 8/11/2017 | Amy Trojanowski | VP | Sell | 2,500 | $46.03 | $115,075.00 | | |
| 8/11/2017 | E Bryan Snell | Insider | Sell | 10,000 | $46.24 | $462,400.00 | | |
| 6/5/2017 | Paul Kirsch | Insider | Sell | 19,036 | $41.42 | $788,471.12 | | |
| 5/16/2017 | Erich Parker | VP | Sell | 4,908 | $45.53 | $223,461.24 | | |
| 5/5/2017 | Mark Newman | VP | Sell | 22,781 | $39.83 | $907,367.23 | | |
| 5/3/2017 | Richard H. Brown | Director | Buy | 2,500 | $39.10 | $97,750.00 | | |
| 5/13/2016 | Mark Newman | CFO | Buy | 2,800 | $9.71 | $27,188.00 | 108,533 | |
| 5/4/2016 | Bradley J Bell | Director | Buy | 10,000 | $9.65 | $96,500.00 | 21,747 | |
| 2/26/2016 | Stephen D. Newlin | Director | Buy | 10,000 | $4.94 | $49,400.00 | | |
| 11/23/2015 | Thierry Fj Vanlancker | Insider | Buy | 15,000 | $6.00 | $90,000.00 | 190,022 | |
| 9/14/2015 | E Bryan Snell | Insider | Buy | 8,000 | $8.89 | $71,120.00 | 22,051 | |
| 9/11/2015 | Amy Trojanowski | VP | Buy | 5,400 | $9.24 | $49,896.00 | 11,982 | |
| 9/10/2015 | Christian W Siemer | Insider | Buy | 10,100 | $9.39 | $94,839.00 | 31,843 | |
| 9/9/2015 | Mark Newman | CFO | Buy | 10,600 | $9.32 | $98,792.00 | 114,109 | |
| 9/8/2015 | Christian W Siemer | Insider | Buy | 11,000 | $9.11 | $100,210.00 | 21,743 | |
| 9/4/2015 | David C Shelton | SVP | Buy | 5,000 | $9.00 | $45,000.00 | 13,183 | |
| 9/4/2015 | Mark P Vergnano | CEO | Buy | 72,600 | $9.25 | $671,550.00 | 321,337 | |
| 9/4/2015 | Stephen D. Newlin | Director | Buy | 7,000 | $9.18 | $64,260.00 | 16,680 | |
(Data available from 1/1/2013 forward)
The Chemours (NYSE CC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | The Chemours Company (CC) SVP Sells $260,000.00 in Stock
www.americanbankingnews.com - April 19 at 10:10 PM |
| Chemours (CC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM |
 | 'Fast and loose': Plaintiffs respond to motion to dismiss GenX case
www.bizjournals.com - April 17 at 9:53 AM |
 | 'Fast and loose': Plaintiffs respond to motion to dismiss GenX case
finance.yahoo.com - April 16 at 4:22 PM |
| Jefferies Group Raises Chemours (CC) Price Target to $60.00
www.americanbankingnews.com - April 13 at 7:49 PM |
| Chemours (CC) Rating Increased to Neutral at UBS
www.americanbankingnews.com - April 13 at 12:58 AM |
 | June 1st Options Now Available For Chemours (CC)
www.nasdaq.com - April 12 at 4:19 PM |
 | Why Chemours Company (CC) Could Beat Earnings Estimates Again April 11, 2018
www.zacks.com - April 12 at 10:38 AM |
| Why Chemours Company (CC) Could Beat Earnings Estimates Again
finance.yahoo.com - April 11 at 10:28 AM |
| Citigroup Lowers Chemours (CC) Price Target to $66.00
www.americanbankingnews.com - April 10 at 11:29 AM |
| NC puts Chemours on notice over GenX air emissions
www.bizjournals.com - April 9 at 4:16 PM |
| Why Chemours Company (CC) Could Be an Impressive Growth Stock April 09, 2018
www.zacks.com - April 9 at 4:16 PM |
| Analyzing Innospec (IOSP) and Chemours (CC)
www.americanbankingnews.com - April 6 at 9:26 PM |
| Chemours Co (CC) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 5 at 1:44 PM |
| Top Ranked Value Stocks to Buy for April 5th
finance.yahoo.com - April 5 at 8:49 AM |
| Is Chemours (CC) a Great Stock for Value Investors?
www.nasdaq.com - April 4 at 5:14 PM |
| Chemours (CC) Upgraded to B- by TheStreet
www.americanbankingnews.com - April 4 at 12:49 PM |
| Chemours (CC) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 6:26 PM |
| Zacks.com highlights: Chemours, Activision Blizzard, Jones Lang LaSalle, Avery Dennison and Applied Materials
finance.yahoo.com - April 3 at 10:06 AM |
| Chemours (CC) Looks Good: Stock Adds 5.4% in Session April 02, 2018
www.zacks.com - April 2 at 10:26 AM |
| Chemours (CC) Looks Good: Stock Adds 5.4% in Session
www.nasdaq.com - April 2 at 10:26 AM |
 | Barclays Remains Bullish on Chemours (CC)
www.streetinsider.com - March 29 at 10:13 AM |
| Chemours Co to Post Q4 2018 Earnings of $1.47 Per Share, Jefferies Group Forecasts (CC)
www.americanbankingnews.com - March 29 at 8:13 AM |
| Research Analysts Set Expectations for Chemours Co's Q1 2018 Earnings (CC)
www.americanbankingnews.com - March 28 at 6:34 AM |
| Chemours (CC) Now Covered by BMO Capital Markets
www.americanbankingnews.com - March 27 at 5:44 PM |
| Here's Why You Should Add Chemours (CC) to Your Portfolio
www.zacks.com - March 27 at 4:19 PM |
| Here's Why You Should Add Chemours (CC) to Your Portfolio
finance.yahoo.com - March 27 at 4:19 PM |
 | Teflon maker Chemours sees more profit in 2018
www.marketwatch.com - March 27 at 9:56 AM |
 | Chemours sees full-year earnings at high end of prior guidance
seekingalpha.com - March 27 at 9:56 AM |
| Chemours (CC) Coverage Initiated at Morgan Stanley
www.americanbankingnews.com - March 26 at 3:13 PM |
| Financial Contrast: Platform Specialty Products (PAH) vs. Chemours (CC)
www.americanbankingnews.com - March 21 at 5:18 PM |
| Chemours Company, (The) -- Moody's assigns Baa3 to Chemours' New Senior Secured Credit facilities
finance.yahoo.com - March 20 at 9:43 AM |
| Access Group, Inc. Series 2007-1 -- Moody's assigns Baa3 to Chemours' New Senior Secured Credit facilities
finance.yahoo.com - March 19 at 4:19 PM |
| Why Analysts Are Positive on W.R. Grace
finance.yahoo.com - March 16 at 4:23 PM |
| Top Ranked Value Stocks to Buy for March 16th
finance.yahoo.com - March 16 at 10:47 AM |
| PPG Industries to Hike Price of Automotive OEM Coatings
finance.yahoo.com - March 15 at 4:16 PM |
| Nucor (NUE) Set to Construct Rebar Micro Mill in Florida
finance.yahoo.com - March 14 at 12:36 PM |
| Reviewing Albemarle (ALB) and Chemours (CC)
www.americanbankingnews.com - March 11 at 4:02 PM |
| Chemours Co (CC) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 12:47 PM |
| Insider Selling: Chemours Co (CC) VP Sells 29,381 Shares of Stock
www.americanbankingnews.com - March 10 at 4:21 AM |
| Head to Head Survey: Taminco (TAM) & Chemours (CC)
www.americanbankingnews.com - March 8 at 5:24 AM |
 | Thinking about buying or selling stock or options in Boeing, Chemours Co, Myomo Inc, Netflix and Visa?
www.prnewswire.com - March 5 at 9:52 AM |
| Maverick Capital Ltd. Purchases 42,650 Shares of Chemours Co (CC)
www.americanbankingnews.com - March 4 at 1:40 PM |
| Chemours Co (CC) Position Raised by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 3 at 9:08 AM |
 | What Does 3M's $850 Million Legal Settlement Mean for Chemours ... - Motley Fool
www.fool.com - March 2 at 4:13 PM |
| Martingale Asset Management L P Trims Stake in Chemours Co (CC)
www.americanbankingnews.com - March 1 at 9:34 AM |
| Allianz Asset Management GmbH Decreases Position in Chemours Co (CC)
www.americanbankingnews.com - March 1 at 4:10 AM |
| Chemours Co (CC) Shares Bought by Horizon Investment Services LLC
www.americanbankingnews.com - February 28 at 4:50 PM |
| What Does 3M's $850 Million Legal Settlement Mean for Chemours Company?
finance.yahoo.com - February 28 at 4:19 PM |
| Chemours Company, (The) -- Moody's says risk to Chemours and DuPont steps up with new PFC litigation
finance.yahoo.com - February 27 at 4:20 PM |
The Chemours (NYSE:CC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
The Chemours (NYSE:CC) Income Statement, Balance Sheet and Cash Flow Statement
The Chemours (NYSE CC) Stock Chart for Friday, April, 20, 2018
Loading chart…
